| Active substance |
Semaglutid |
| Also known as |
N/A |
| Blood pressure |
Can cause a reduction in blood pressure |
| Chemical name |
Semaglutide |
| Dosage (medical) |
0.25 mg once weekly, increasing to 0.5 mg and up to 1 mg as tolerated and needed |
| Dosage (sports) |
Not recommended for use in sports |
| Effects |
Improved glycemic control, weight loss |
| Formula |
C187H291N45O59 |
| Half-life |
Approximately 1 week |
| Hepatotoxicity |
Low risk |
| Lab Test |
Blood glucose levels, HbA1c |
| Main action |
Lowers blood glucose levels |
| Side effects |
Nausea, vomiting, diarrhea, abdominal pain, decreased appetite |
| Storage conditions |
Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F) |
| Substance class |
GLP-1 receptor agonist |
| Trade name |
Ozempic, Rybelsus |
| Use in sports |
None, not indicated for performance enhancement |
| Water Retention |
Minimal |
| Active ingredient, mg |
1 |
| Release form |
Cartridge |
| Manufacturer |
Novo Nordisk |
| Packing |
Package (1 cartridge) |
